Participant Flow: Study measurement



Baseline Characteristics

Characteristic	*AIS/TIA (n=232)*	*AIS (n=151)*	*TIA (n=81)*
Demographics			
Age (years)	71 (64-79)	71 (64-79)	68 (60-76)
Male, n (%)	146 (62.9%)	102 (67.6%)	44 (54.3%)
Ethnicity, White British, n (%)	211 (90.9%)	140 (92.7%)	71 (87.7%)
BMI, kg/m^2	26.1 (23.4-29.1)	26.2 (23.6-29.7)	25.8 (23.4-28)
Past Medical History			
Hypertension, n (%)	118 (50.9%)	79 (52.3%)	39 (48.2%)
Hypercholesterolaemia, n (%)	68 (29.3%)	45 (29.8%)	23 (28.4%)
TIA or Stroke, n (%)	45 (19.4%)	30 (19.9%)	15 (18.5%)
Diabetes, n (%)	36 (15.5%)	24 (15.9%)	12 (14.8%)
MI, n (%)	10 (4.3%)	9 (6%)	1 (1.2%)
Atrial Fibrillation, n (%)	1 (0.4%)	0	1 (1.2%)
Angina, n (%)	13 (5.6%)	11 (7.3%)	2 (2.5%)
Angioplasty, n (%)	3 (1.3%)	2 (1.3%)	1 (1.2%)
CABG, n (%)	3 (1.3%)	3 (2%)	0
Heart valve disease, n (%)	5 (2.2%)	3 (2%)	2 (2.5%)
Heart Failure, n (%)	1 (0.4%)	1 (0.7%)	0
Internal Cardiac Defibrillator, n (%)	1 (0.4%)	1 (0.7%)	0
Leg Angioplasty, n (%)	1 (0.4%)	1 (0.7%)	0
PVD, n (%)	9 (3.9%)	9 (6%)	0
Medication History			
Anti-hypertensive therapy	107 (46.1%)	73 (48.3%)	34 (42%)
1 drug	65 (28%)	43 (28.5%)	22 (27.2%)
≥2 drugs	42 (18.1%)	30 (19.9%)	12 (14.8%)
Anti-platelet therapy	68 (29.3%)	49 (32.5%)	19 (23.5%)
1 drug	66 (28.5%)	49(32.5%)	27 (21%)
≥2 drugs	2 (0.9%)	0	2 (2.5%)
Warfarin	1 (0.4%)	0	1 (1.2%)
Cholesterol lowering therapy	84 (36.4%)	60 (39.7%)	24 (29.6%)
1 drug	83 (36.2%)	59 (39.1%)	24 (29.6%)
≥2 drugs	1 (0.4%)	1 (0.7%)	0
Social History			
Never smoked	88 (37.9%)	51 (33.8%)	37 (45.7%)
Former smoker	108 (45.9%)	77 (51%)	31 (38.3%)
Current smoker	35 (15.2%)	22 (14.6%)	13 (16.1%)
Weekly alcohol units	4 (0-10)	4 (0-10)	3 (0-11)
Family History			
MI	38 (16.4%)	25 (16.6%)	13 (16.1%)
IHD	47 (20.3%)	22 (14.6%)	25 (31.2%)
Stroke	62 (26.7%)	33 (21.9%)	29 (37.6%)
Hypertension	34 (14.7%)	21 (13.9%)	13 (15.1%)
Hypercholesterolaemia	12 (5.2%)	9 (6%)	3 (3.2%)
Clinical features			
Admission systolic BP, mm Hg	153 (138-176)	156 (140-175)	150 (133-174)
Admission diastolic BP, mm Hg	84 (75-98)	85 (75-98)	83 (73-98)
Admission pulse pressure , mm Hg	70 (55-88)	71 (56-88)	65 (54-89)
Pre-stroke mRS	0 (0-1)	0 (0-1)	0 (0-1)
Pre-stroke mRS 0	164 (70.7%)	105 (69.5%)	59 (52.8%)
Pre-stroke mRS ≥1	64 (27.6%)	43 (28.5%)	21 (25.9%)
Admission mRS	2 (1-3)	3 (2-3)	1 (0-2)
Admission mRS <3	99 (42.7%)	68 (45%)	31 (38.3%)
Admission mRS ≥3	72 (31%)	69 (45.7%)	3 (3.7%)

Admission NIHSS	2 (0-6)	4 (2-7)	0
Admission NIHSS ≤8	201 (86.6%)	122 (80.8%)	79 (97.5%)
Admission NIHSS>8	27 (11.6%)	27 (17.9%)	0
Thrombolysed	40 (17.2%)	40 (26.5%)	0
Normal ECG *Abnormal* ECG	199 (85.8%) 21 (9.1%)	124 (82.1%) 21 (9.1%)	75 (92.6%) 0
Routine Laboratory Investigations			
Glucose, mmol/L	5 (4.2 - 6)	6.3 (5.4-7.9)	5.5 (4.9 -6.1)
Total Cholesterol, mmol/L	5 (4.2 - 6)	4.9 (4 – 5.9)	5.4 (4.4- 6.3)
HDL, mmol/L	1.4 (1.1 - 1.8)	1.3 (1-2)	1.4 (1.1 -1.8)
LDL, mmol/L	2.8 (2.1 - 4.1)	2.8 (2.2 -4.3)	2.8 (2.1 -3.8)
Triglycerides, mmol/L	1.7 (0.96 - 2.2)	1.7 (1.3 -2.4)	1.7 (0.9-2.2)
Creatinine μmol/L	7 (65 - 89)	78 (66.5 -91)	75.5 (61-87)
Bilirubin, mg/dl	9 (7-11)	9 (7-11.5)	9 (7-11)
ALT, units/L	19 (15-29.5)	20.5 (15-31)	19 (14-28)
ALP, units/ L	75 (61-93)	76 (61 -92.5)	69.5 (60-930
eGFR <60 ml/min/1.73m²	33 (14.2%)	23 (15.2%)	11 (13.6%)
Hb g/L	137 (120 -148)	137 (113-147)	138 (127 -150)
WBC 10^9/L	7.6 (5.9 -9.4)	7.7 (5.9 -9.7)	7 (5.9- 8.5)
Diagnostic Imaging			
CT	162 (69.8%)	121 (80.1%)	41 (50.6%)
MRI	64 (29.4%)	20 (13.2%)	44 (54.3%)
Both CT and MRI	8 (3.4%)	1 (0.7%)	7 (8.6%)
Carotid ultrasound	133 (57.3%)	90 (59.6%)	43 (53.1%)
Stroke Subtype			
TACS	11 (4.7%)	11 (8%)	0
PACS	72 (31%)	71 (50%)	1 (1.2%)
LACS	41 (17.7%)	40 (26.8%)	1 (1.2%)
POCS	24 (10.3%)	23 (14.5%)	1 (1.2%)
Site of Lesion			
Right Hemisphere	36 (15.5%)	35 (23.2%)	1 (1.2%)
Left Hemisphere	36 (15.5%)	34 (22.5%)	2 (2.5%)
Both Hemispheres	2 (0.9%)	2 (1.3%)	0
Carotid territory TIA	53 (22.8%)	0	53 (65.4%)
Posterior circulation territory TIA	19 (8.2%)	0	19 (23.5%)

Baseline study population described by demographic data and clinical features have been reported by the entire study cohort, and by AIS and TIA subgroups. Data are n (%) and median (IQR). ALP, Alkaline phosphatase; ALT, alanine aminotransferase; BMI, Body Mass Index; BP, Blood Pressure; CABG, coronary artery bypass grafting; ECG, electrocardiogram; eGFR, estimated Glomerular filtration Rate; Hb, Haemoglobin; HDL, high-density lipoprotein; IHD, Ischaemic Heart Disease; LACS, Lacunar Stroke Syndrome; LDL, low-density lipoprotein; MI, Myocardial Infarction; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; PACS, Partial Anterior Circulation Stroke Syndrome; POCS, Posterior Circulation Stroke Syndrome; PVD, peripheral vascular disease; TACS, Total Anterior Circulation Stroke Syndrome; TIA, Transient Ischaemic Attack; WBC, white blood cell

Outcome Measures

Primary Outcome Measure	
Modified Rankin Score >2 at 3 months	34

Secondary Outcome Measure	
Short-term (72 hours)	
Neurological deterioration/ improvement (NIHSS score increase/ decrease by >4 points, respectively), n	Neurological deterioration=0 Neurological improvement=1
Hospital discharge	
Mortality, n	1
Recurrent TIA/stroke, n	1
Major cardiovascular events (non-fatal and fatal stroke, myocardial infarction and systemic embolism), n	5
mRS >2, n	33
Length of hospital stay	n/a
Medium-term (1 month)	
Mortality, n	1
Recurrent TIA/stroke, n	5
Major cardiovascular events , n	3
mRS >2, n	45
Cognitive dysfunction assessed using the Montreal Cognitive Assessment tool (MoCA) <26, n	66
Medium-term (3 months)	
Mortality, n	2
Recurrent TIA/stroke, n	5
Major cardiovascular events , n	0
mRS >2, n	34
Cognitive dysfunction assessed, MoCA <26, n	43
Long-term (1 year)	
Mortality, n	3
Recurrent TIA/stroke, n	9
Major cardiovascular events , n	0
mRS >2, n	37
Cognitive dysfunction assessed, MoCA <26, n	31
Time to death/hospital re-admission	n/a

Adverse Events

There were no adverse events associated with this trial